Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Delaware for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Delaware only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Delaware (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Evan Lapinsky (NPI 1134486046)

Field	Value
Entity Type	Individual
Organization	Evan Lapinsky
Address	4701 Ogletown Stanton Rd Ste 3400
City	Newark
State	DE
ZIP	19713
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 16, 2012

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the dataset: total Medicare revenue is $1.7M while Medicaid billing is recorded as none, indicating the practice’s revenue and utilization profile in this data is driven entirely by Medicare patients. That concentration in a single public payer should be considered when assessing reimbursement risk and market exposure.

Revenue is highly concentrated in a small set of drug‑administration codes: the precomputed top 3 Medicare codes by revenue account for 78.9% of this provider’s total Medicare revenue, with J9271 alone representing $842.8K (51.5%) and J9144 contributing $376.2K (23.0%). J0897 is the third top driver at $72.4K (4.4%), so the practice’s economics are dominated by a few high‑revenue oncology agents rather than by broad E/M billing.

The procedural mix indicates an outpatient oncology infusion model focused on high‑cost biologic and immunotherapy administration: large volumes of J9271 (pembrolizumab) and J9144 (daratumumab) combined with chemotherapy administration codes such as 96413, 96417 and add‑on infusion codes point to routine in‑office or clinic infusion services. Presence of G0498 (infusion initiation with community continuation) further supports a workflow that includes portable pump or home‑continuation infusion management.

Competitive standing on the largest revenue drivers looks modest rather than dominant nationally: J9271 ranks #417 of 1841 (77th percentile) and is labeled as a typical, unremarkable volume for that code, while J9144 ranks #213 of 615 (64th percentile) and J0897 ranks #3493 of 10057 (65th percentile), both also described as typical. In other words, the provider is an active but not top‑tier national participant for these high‑value oncology drugs.

There are a few statistically notable deviations from the typical pattern: J1454 ranks #32 of 422 (92th percentile) and is flagged as notably above typical national volume despite representing only $47.9K (2.9%) of Medicare revenue, which suggests unusually frequent use of that fosnetupitant/palonosetron combination for antiemetic support relative to peers. By contrast, J1568 (immune globulin) sits at the 12th percentile (#336 of 381), indicating relatively lower use of that product compared with the national sample.

Evaluation‑and‑management activity shows sustained outpatient follow‑up: 99214 appears with 444 claims and $43.5K (2.7% of Medicare revenue) and ranks at the 88th percentile, while 99215 (149 claims, $20.9K, 1.3%) is at the 87th percentile, implying the provider maintains regular established‑patient clinic visits and potentially manages ongoing systemic therapy regimens. These higher E/M percentiles are consistent with a practice that pairs frequent infusion visits with substantive clinical follow‑up.

The provider’s business model carries concentration risk tied to oncology biologics and immunotherapies: with a single drug, J9271, accounting for 51.5% of Medicare revenue and the top 3 codes together 78.9%, changes in utilization guidelines, coverage, or reimbursement for these agents would disproportionately affect revenue. This profile also creates potential leverage points for payer negotiations or care‑pathway management given the predictable drug mix.

Tenure and market footprint are established: the NPI was enumerated on 2012-04-16 (~14 years ago) and the provider practice is in NEWARK, DE, indicating a long‑standing local presence which may support steady referral patterns for outpatient oncology infusions even though national rank percentiles place the provider as a moderate rather than dominant national participant.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,600	$40	$842.8K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,900	$40	$376.2K
J0897	Injection, denosumab, 1 mg	4,020	$20	$72.4K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	1,430	$30	$48.6K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	140	$350	$47.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	420	$110	$44.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	440	$100	$43.5K
J1437	Injection, ferric derisomaltose, 10 mg	1,700	$20	$27.2K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	280	$100	$26.5K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	150	$140	$20.9K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Delaware Distribution

Evan Lapinsky — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Delaware

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	5	10	17,600	$40	$992.4K
J9144	2	10	9,360	$40	$420.8K
J1568	3	10	2,660	$30	$146.7K
J0897	24	60	3,360	$20	$132.9K
Q5122	5	10	400	$100	$61.8K
J1437	5	10	1,800	$20	$47.1K
J1454	2	10	90	$340	$38.1K
96413	10	30	280	$100	$36.6K
99214	385	1,830	150	$80	$25.5K
96401	14	30	110	$60	$18.4K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Evan Lapinsky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Medical Oncology Hematology Consultants PA	DE	Hematology & Oncology Physician	$0	$7.7M
Jamal Misleh	DE	Hematology & Oncology Physician	$6.8M	$0
Dhaval Shah	DE	Hematology & Oncology Physician	$2.5M	$0
Gregory Masters	DE	Medical Oncology Physician	$2.3M	$0
Lydia Clements	DE	Medical Oncology Physician	$1.3M	$0
Sujung Park	DE	Hematology & Oncology Physician	$1.2M	$0
Amy Mcghee Jez	DE	Hematology & Oncology Physician	$1.1M	$0
Andrew Himelstein	DE	Hematology & Oncology Physician	$1.1M	$0
Roberto Ferro Valdes	SD	Hematology & Oncology Physician	$1.1M	$0
Martha Hosford Skapof	DE	Hematology & Oncology Physician	$748.2K	$0

Nearby Providers

Other providers in the same ZIP code as Evan Lapinsky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Retinal Consultants LLC	DE	Ophthalmology Physician	$0	$25.2M
Columbus Medical Services, LLC	DE	Case Management Agency	$0	$18.7M
Christiana Care Health Services Inc	DE	Hospitalist Physician	$0	$13.6M
Caritas Home Health Services, Inc	DE	Home Health Agency	$0	$11.2M
Delaware Center For Maternal Fetal Medicine Of Christiana Care	DE	Maternal & Fetal Medicine Physician	$0	$9.8M
Christiana Care Health Services Inc	DE	Neonatal-Perinatal Medicine Physician	$0	$8.9M
Christiana Care Quality Partners	DE	Urgent Care Clinic/Center	$0	$7M
Mid-atlantic Behavioral Health, LLC	DE	Intellectual & Developmental Disabilities Psychologist	$0	$6.5M
First State Orthopaedics, PA	DE	Orthopaedic Surgery Physician	$0	$6M
Autism Delaware	DE	Intellectual & Developmental Disabilities Psychologist	$0	$5.8M

Evan Lapinsky — Billing Profile & Reimbursement Data

Sign up for Evan Lapinsky — Billing Profile & Reimbursement Data policy alerts

Evan Lapinsky — Billing Profile & Reimbursement Data

Sign up for Evan Lapinsky — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References